Search Result

Results for "

transmitters

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Adrenergic Receptor (2) Apoptosis (11) Dopamine Receptor (1) Dopamine Transporter (1) Drug Metabolite (2) Endogenous Metabolite (12) Ferroptosis (11) GABA Receptor (1) iGluR (13) Isotope-Labeled Compounds (6) Monoamine Transporter (1) PKC (1) Potassium Channel (5) Reference Standards (4)
By Research Areas:	Cardiovascular Disease (1) Neurological Disease (27)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1348

Dimethadione	Drug Metabolite	Neurological Disease
Dimethadione is the primary metabolite of trimethadione. Dimethadione causes depression of neuromuscular transmission. Dimethadione primarily decreases transmitter release from the nerve terminal .

HY-108256

Melitracen hydrochloride	5-HT Receptor	Neurological Disease
Melitracen hydrochloride is an orally active biphasic antidepressant and antianxiety agent. Melitracen hydrochloride can inhibit the uptake of Norepinephrine and 5-HT (serotonin) through the presynaptic membrane inducing the increase of monoamine transmitters in synaptic space .

HY-B1348R

Dimethadione (Standard)	Reference Standards Drug Metabolite	Neurological Disease
Dimethadione (Standard) is the analytical standard of Dimethadione. This product is intended for research and analytical applications. Dimethadione is the primary metabolite of trimethadione. Dimethadione causes depression of neuromuscular transmission. Dimethadione primarily decreases transmitter release from the nerve terminal[1].

HY-120524

CGP 31358	iGluR	Neurological Disease
CGP 31358 is an anticonvulsant agent that binds to a site on the NMDA receptor complex that is coupled to both the transmitter recognition site and to the channel domain. CGP 31358 inhibits the binding of L-Glutamate to the NMDA receptor complex with an IC₅₀ of 53 μM .

HY-108256R

Melitracen hydrochloride (Standard)	5-HT Receptor Reference Standards	Neurological Disease
Melitracen (hydrochloride) (Standard) is the analytical standard of Melitracen (hydrochloride). This product is intended for research and analytical applications. Melitracen hydrochloride is an orally active biphasic antidepressant and antianxiety agent. Melitracen hydrochloride can inhibit the uptake of Norepinephrine and 5-HT (serotonin) through the presynaptic membrane inducing the increase of monoamine transmitters in synaptic space .

HY-133596

12,14-Dichlorodehydroabietic acid	Potassium Channel GABA Receptor	Neurological Disease
12,14-Dichlorodehydroabietic acid, a chlorinated resin acid, is a potent Ca ²⁺-activated K ⁺ (BK) channel opener. 12,14-Dichlorodehydroabietic acid blocks GABA-dependent chloride entry in mammalian brain and operates as a non-competitive GABA_A antagonist. 12,14-Dichlorodehydroabietic acid increases cytosolic free Ca ²⁺ and stimulates transmitter release .

HY-P1725

Leucomyosuppressin	Endogenous Metabolite	Neurological Disease
Leucomyosuppressin, an insect neuropeptide, is an inhibitory myotropic peptide. Leucomyosuppressin inhibits evoked transmitter release at the mealworm neuromuscular junction .

HY-B1251

Guanethidine	Adrenergic Receptor	Cardiovascular Disease Neurological Disease
Guanethidine sulphate was synthesized in 1959. Guanethidine is thought to lowing blood pressure by interfering with the metabolism of chemical transmitter substances in post-ganglionic sympathetic nerve fibres.

HY-W354635

N-Methyl-2-phenylpropan-1-amine hydrochloride	Dopamine Transporter Monoamine Transporter	Neurological Disease
N-Methyl-2-phenylpropan-1-amine hydrochloride is a β-Methylphenethylamine (BMPEA) analog, and has transmitter releasing action at NET and DAT assay .

HY-P1716

Neuropeptide DF2	PKC	Neurological Disease
Neuropeptide DF2 is a DRNFLRFamide neuropeptide orignally isolated from crayfish. which enhances transmitter release and stimulates the amplitude of excitatory post-synaptic potentials (EPSP) through the calcium/calmodulin-dependent protein kinase .

HY-108256S

Melitracen-d6 hydrochloride	Isotope-Labeled Compounds 5-HT Receptor	Neurological Disease
Melitracen-d₆ (hydrochloride) is the deuterium labeled Melitracen hydrochloride. Melitracen hydrochloride is an orally active biphasic antidepressant and antianxiety agent. Melitracen hydrochloride can inhibit the uptake of Norepinephrine and 5-HT (serotonin) through the presynaptic membrane inducing the increase of monoamine transmitters in synaptic space .

HY-14608S8

L-Glutamic acid-d3	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-d₃ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S

L-Glutamic acid-13C	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S7

L-Glutamic acid-d5	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-d₅ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S2

L-Glutamic acid-15N	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹⁵N is the ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .

HY-14608S5

L-Glutamic acid-13C5	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹³C₅ is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S10

L-Glutamic acid-13C2	Apoptosis iGluR Ferroptosis Endogenous Metabolite	Neurological Disease
L-Glutamic acid- ¹³C₂ is the ¹³C labeled L-Glutamic acid . L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .

HY-14608S6

L-Glutamic acid-5-13C	Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-5- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S1

L-Glutamic acid-1-13C	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid-1- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S3

L-Glutamic acid-13C5,15N	Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹³C₅, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S9

L-Glutamic acid-15N,d5	Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹⁵N,d₅ is the deuterium and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14946

Amifampridine 3,4-Diaminopyridine	Potassium Channel	Neurological Disease
Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (K_v) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .

HY-14608S4

L-Glutamic acid-13C5,15N,d5	Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹³C₅, ¹⁵N,d₅ is the deuterium, ¹³C-, and 15-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14946A

Amifampridine phosphate 3,4-Diaminopyridine phosphate	Potassium Channel	Neurological Disease
Amifampridine (3,4-Diaminopyridine) phosphate is an orally active, potent and cell permeable voltage-gated potassium (K_v) channel blocker (PCB). Amifampridine phosphate is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine phosphate increases transmitter release from neuromuscular junctions (NMJs). Amifampridine phosphate can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .

HY-19225A

Ensaculin free base KA-672; Anseculin	iGluR 5-HT Receptor Adrenergic Receptor Dopamine Receptor	Neurological Disease
Ensaculin free base (KA-672) is a NMDA antagonist and have high affinities to serotonergic 5-HT_1A and 5-HT₇ receptors, adrenergic α₁, and dopaminergic D₂ and D₃ receptors. Ensaculin free base is a memory-enhancing agent. Ensaculin free base has the potential as an antidementia agent acting on various transmitter systems .

HY-14946R

Amifampridine (Standard) 3,4-Diaminopyridine (Standard)	Reference Standards Potassium Channel	Neurological Disease
Amifampridine (Standard) is the analytical standard of Amifampridine. This product is intended for research and analytical applications. Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .

HY-W002097R

1-(5-Methylthiophen-2-yl)ethan-1-one (Standard) 2-Acetyl-5-methylthiophene (Standard)	Reference Standards Others	Others
Amifampridine (Standard) is the analytical standard of Amifampridine. This product is intended for research and analytical applications. Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .

HY-14946S

Amifampridine-d3 3,4-Diaminopyridine-d₃	Isotope-Labeled Compounds Potassium Channel	Neurological Disease
Amifampridine-d₃ (3,4-Diaminopyridine-d₃) is deuterium labeled Amifampridine. Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (K_v) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .

Cat. No.	Product Name

HY-L212

Neuropeptide Library	110 compounds
Neuropeptides are small proteins produced and released by neurons through the regulation of secretory pathways, expressed in neurons and have transmitter or co-transmitter functions, and are used as nerve substrates. Neuropeptides are by far the largest and most diverse signaling molecules in the brain and have been implicated in the development of diseases and drugs. Neuropeptides are involved in inflammatory and immune diseases and have an impact on epithelial, vascular, and connective tissue cells proliferation and tissue repair. Studies have shown that neuropeptides are particularly important when the nervous system is challenged, such as stress, injury, or substance abuse. Substance P is a neuropeptide that acts as a neurotransmitter and neuromodulator in the central nervous system and is currently in clinical research and has been shown to be involved in inflammatory processes and pain. MCE can provide 110 neuropeptides that can be used for scientific research.

Neuropeptide Library

110 compounds

Neuropeptides are small proteins produced and released by neurons through the regulation of secretory pathways, expressed in neurons and have transmitter or co-transmitter functions, and are used as nerve substrates. Neuropeptides are by far the largest and most diverse signaling molecules in the brain and have been implicated in the development of diseases and drugs. Neuropeptides are involved in inflammatory and immune diseases and have an impact on epithelial, vascular, and connective tissue cells proliferation and tissue repair. Studies have shown that neuropeptides are particularly important when the nervous system is challenged, such as stress, injury, or substance abuse. Substance P is a neuropeptide that acts as a neurotransmitter and neuromodulator in the central nervous system and is currently in clinical research and has been shown to be involved in inflammatory processes and pain.

MCE can provide 110 neuropeptides that can be used for scientific research.

Cat. No.	Product Name	Target	Research Area

HY-P1725

Leucomyosuppressin	Endogenous Metabolite	Neurological Disease
Leucomyosuppressin, an insect neuropeptide, is an inhibitory myotropic peptide. Leucomyosuppressin inhibits evoked transmitter release at the mealworm neuromuscular junction .

HY-P1716

Neuropeptide DF2	PKC	Neurological Disease
Neuropeptide DF2 is a DRNFLRFamide neuropeptide orignally isolated from crayfish. which enhances transmitter release and stimulates the amplitude of excitatory post-synaptic potentials (EPSP) through the calcium/calmodulin-dependent protein kinase .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W002097R

1-(5-Methylthiophen-2-yl)ethan-1-one (Standard) 2-Acetyl-5-methylthiophene (Standard)	Structural Classification Natural Products Source classification Rubiaceae Plants Coffea arabica L.	Reference Standards Others
Amifampridine (Standard) is the analytical standard of Amifampridine. This product is intended for research and analytical applications. Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .

Cat. No.	Product Name	Chemical Structure

HY-14608S8

L-Glutamic acid-d3
L-Glutamic acid-d₃ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S7

L-Glutamic acid-d5
L-Glutamic acid-d₅ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S2

L-Glutamic acid-15N
L-Glutamic acid- ¹⁵N is the ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .

HY-14608S5

L-Glutamic acid-13C5
L-Glutamic acid- ¹³C₅ is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S1

L-Glutamic acid-1-13C
L-Glutamic acid-1- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S3

L-Glutamic acid-13C5,15N
L-Glutamic acid- ¹³C₅, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-108256S

Melitracen-d6 hydrochloride
Melitracen-d₆ (hydrochloride) is the deuterium labeled Melitracen hydrochloride. Melitracen hydrochloride is an orally active biphasic antidepressant and antianxiety agent. Melitracen hydrochloride can inhibit the uptake of Norepinephrine and 5-HT (serotonin) through the presynaptic membrane inducing the increase of monoamine transmitters in synaptic space .

HY-14608S

L-Glutamic acid-13C
L-Glutamic acid- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S10

L-Glutamic acid-13C2
L-Glutamic acid- ¹³C₂ is the ¹³C labeled L-Glutamic acid . L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .

HY-14608S6

L-Glutamic acid-5-13C
L-Glutamic acid-5- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S9

L-Glutamic acid-15N,d5
L-Glutamic acid- ¹⁵N,d₅ is the deuterium and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S4

L-Glutamic acid-13C5,15N,d5
L-Glutamic acid- ¹³C₅, ¹⁵N,d₅ is the deuterium, ¹³C-, and 15-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14946S

Amifampridine-d3

Amifampridine-d₃ (3,4-Diaminopyridine-d₃) is deuterium labeled Amifampridine. Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (K_v) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

transmitters

Inhibitors & Agonists

Screening Libraries

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products